Glutamate receptor ionotropic, NMDA 1 (GluN1) (GluN1)

The Glutamate receptor ionotropic, NMDA 1 (GluN1) subunit is the essential, ubiquitously expressed component of the N-methyl-D-aspartate (NMDA) receptor complex, a key mediator of excitatory signaling and synaptic plasticity in the brain [Source: UniProt P35439]. Unlike other subunits that bind glutamate, GluN1 contains the obligatory binding site for co-agonists glycine and D-serine, which must be occupied for the channel to open upon glutamate binding [Source: PubMed PMID: 11518769]. This "glycine site" serves as a critical rheostat for NMDA receptor activity, influencing calcium influx and downstream signaling pathways involved in learning and memory [Source: StatPearls]. Dysregulation of GluN1-mediated signaling is linked to the pathophysiology of schizophrenia, where hypofunction is observed, and neurodegenerative diseases or stroke, where overactivation leads to excitotoxicity [Source: PubMed PMID: 25385337]. Pharmacological targeting of the GluN1 glycine site includes the use of partial agonists like D-cycloserine to enhance cognitive function and antagonists like gavestinel for neuroprotection, though clinical success has been limited by narrow therapeutic windows and side effect profiles [Source: PubMed PMID: 15556287].

Other names

NR1GRIN1NMDA receptor subunit 1Glycine-binding site of NMDA receptorGlutamate [NMDA] receptor subunit zeta-1

The GluN1 subunit contains the obligatory co-agonist binding site for glycine or D-serine. Binding at this site is a prerequisite for NMDA receptor channel opening upon glutamate binding to the GluN2 subunit. Drugs targeting this site act as agonists or partial agonists to facilitate channel opening and enhance NMDA-mediated signaling, or as antagonists to block channel activity and provide neuroprotection.